HomeCompareSRRA vs PEP

SRRA vs PEP: Dividend Comparison 2026

SRRA yields 3.64% · PEP yields 3.63%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PEP wins by $116.6K in total portfolio value· pulled ahead in Year 3
10 years
SRRA
SRRA
● Live price
3.64%
Share price
$54.99
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.3K
Annual income
$459.50
Full SRRA calculator →
PEP
PepsiCo Inc.
● Live price
3.63%
Share price
$156.82
Annual div
$5.69
5Y div CAGR
40.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$141.9K
Annual income
$61,875.67
Full PEP calculator →

Portfolio growth — SRRA vs PEP

📍 PEP pulled ahead of the other in Year 3

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSRRAPEP
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SRRA + PEP cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SRRA pays
PEP pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SRRA
Annual income on $10K today (after 15% tax)
$309.15/yr
After 10yr DRIP, annual income (after tax)
$390.58/yr
PEP
Annual income on $10K today (after 15% tax)
$308.41/yr
After 10yr DRIP, annual income (after tax)
$52,594.32/yr
At 15% tax rate, PEP beats the other by $52,203.74/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SRRA + PEP for your $10,000?

SRRA: 50%PEP: 50%
100% PEP50/50100% SRRA
Portfolio after 10yr
$83.6K
Annual income
$31,167.59/yr
Blended yield
37.27%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PEP right now

SRRA
No analyst data
PEP
Analyst Ratings
1
Strong
15
Buy
27
Hold
1
Sell
Consensus: Hold
Price Target
$172.43
+10.0% upside vs current
Range: $156.00 — $191.00
Altman Z
3.6
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SRRA buys
0
PEP buys
0
No recent congressional trades found for SRRA or PEP in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSRRAPEP
Forward yield3.64%3.63%
Annual dividend / share$2.00$5.69
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.4%
Portfolio after 10y$25.3K$141.9K
Annual income after 10y$459.50$61,875.67
Total dividends collected$4.1K$123.0K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: SRRA vs PEP ($10,000, DRIP)

YearSRRA PortfolioSRRA Income/yrPEP PortfolioPEP Income/yrGap
1$11,064$363.70$10,849$509.42+$215.00SRRA
2$12,214$376.07$11,969$750.47+$245.00SRRA
3← crossover$13,457$388.01$13,500$1,124.14$43.00PEP
4$14,799$399.53$15,680$1,721.66$881.00PEP
5$16,245$410.62$18,929$2,715.34$2.7KPEP
6$17,804$421.26$24,023$4,450.80$6.2KPEP
7$19,481$431.47$32,510$7,669.92$13.0KPEP
8$21,286$441.25$47,709$14,093.60$26.4KPEP
9$23,227$450.59$77,415$28,083.48$54.2KPEP
10$25,312$459.50$141,922$61,875.67$116.6KPEP

SRRA vs PEP: Complete Analysis 2026

SRRAStock

Sierra Oncology, Inc., a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally bioavailable Janus kinase 1 (JAK 1), JAK2, and Activin A receptor type 1 (ACVR1) inhibitor. The company also develops SRA515, a selective bromodomain-containing protein 4 inhibitor; and SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1. It has the license agreements with Carna Biosciences, Inc. to develop and commercialize SRA141, a small molecule kinase inhibitor targeting Cdc7; AstraZeneca AB; and CRT Pioneer Fund LP. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was incorporated in 2003 and is headquartered in San Mateo, California. As of July 1, 2022, Sierra Oncology, Inc. operates as a subsidiary of GSK plc.

Full SRRA Calculator →

PEPConsumer Staples

PepsiCo, Inc. manufactures, markets, distributes, and sells various beverages and convenient foods worldwide. The company operates through seven segments: Frito-Lay North America; Quaker Foods North America; PepsiCo Beverages North America; Latin America; Europe; Africa, Middle East and South Asia; and Asia Pacific, Australia and New Zealand and China Region. It provides dips, cheese-flavored snacks, and spreads, as well as corn, potato, and tortilla chips; cereals, rice, pasta, mixes and syrups, granola bars, grits, oatmeal, rice cakes, simply granola, and side dishes; beverage concentrates, fountain syrups, and finished goods; ready-to-drink tea, coffee, and juices; dairy products; and sparkling water makers and related products. It serves wholesale and other distributors, foodservice customers, grocery stores, drug stores, convenience stores, discount/dollar stores, mass merchandisers, membership stores, hard discounters, e-commerce retailers and authorized independent bottlers, and others through a network of direct-store-delivery, customer warehouse, and distributor networks, as well as directly to consumers through e-commerce platforms and retailers. The company was founded in 1898 and is headquartered in Purchase, New York.

Full PEP Calculator →
📬

Get this SRRA vs PEP comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SRRA vs SCHDSRRA vs JEPISRRA vs OSRRA vs KOSRRA vs MAINSRRA vs MOSRRA vs PMSRRA vs GIS

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.